Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 1.00 |
| ▸ | FLT1 | P17948 | 3/20 | 1.00 |
| ▸ | FLT4 | P35916 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | INSR | P06213 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | MARK3 | P27448 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | CLK2 | P49760 | 1/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 1/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 1.00 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13126003 | 0.83 | PRKAB1 (0.72) | KDRFLT1FLT4PLK4AURKA | |
| SCHEMBL4482059 | 0.82 | KDR (0.70) | KDRFLT1FLT4PLK4AURKA | |
| SCHEMBL13822288 | 0.81 | KDR (0.68) | KDRFLT1FLT4PLK4AURKA | |
| SCHEMBL2806481 | 0.80 | KDR (0.67) | KDRFLT1FLT4PLK4AURKA | |
| SCHEMBL2813127 | 0.80 | PRKAB1 (1.00) | KDRFLT1FLT4PLK4AURKA | |
| SCHEMBL19110525 | 0.79 | PRKAB1 (0.67) | KDRFLT1FLT4PLK4AURKA | |
| SCHEMBL19110545 | 0.79 | PRKAB1 (0.67) | KDRFLT1FLT4PLK4AURKA | |
| SCHEMBL19110546 | 0.79 | KDR (0.65) | KDRFLT1FLT4PLK4AURKA | |
| SCHEMBL19123515 | 0.79 | KDR (0.65) | KDRFLT1FLT4PLK4AURKA | |
| SCHEMBL7610618 | 0.79 | KDR (1.00) | KDRFLT1FLT4PLK4AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | claimed |
| EP-0984692-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2001-02-21 | — | — | EP | claimed |
| EP-0984692-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2000-03-15 | — | — | EP | claimed |
| WO-1998054093-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | claimed |
| US-20100240647-A1 | Treatment of Alzheimer's Disease and Related Conditions | MERCK & CO., INC. | 2010-09-23 | — | — | US | disclosed |
| EP-1981509-B1 | Pyrazolo[1,5-a]pyrimidine derivatives for use in treatment of Alzheimer's disease and related conditions | MERCK SHARP & DOHME (GB) | 2010-03-17 | — | — | EP | disclosed |
| EP-1981509-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS | Merck Sharp & Dohme Limited (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085873-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2007-08-02 | — | — | WO | disclosed |
| US-6380203-B1 | PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; TREATMENT OF TYROSINE KINASE-DEPENDENT DISEASES/CONDITIONS SUCH AS ANGIOGENESIS, CANCER, ATHEROSCLEROSIS, DIABETIC RETINOPATHY OR AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2002-04-30 | — | — | US | disclosed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | disclosed |
| US-6235741-B1 | ANTICANCER AGENTS; AUTOIMMUNE DISEASES | MERCK & CO., INC. | 2001-05-22 | — | — | US | disclosed |
| EP-0984692-A4 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO INC (US) | 2001-02-21 | — | — | EP | disclosed |
| EP-0984692-A1 | NOVEL ANGIOGENESIS INHIBITORS | Merck & Co., Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054093-A1 | NOVEL ANGIOGENESIS INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240647-A1 | Treatment of Alzheimer's Disease and Related Conditions | MAPT, MAP2, TTBK1 | KDR 3689/4885FLT1 3092/4885FLT4 3296/4885 |
| US-20020041880-A1 | Method of treating cancer | ACP3, FOLH1, KLK3 | KDR 318/4885FLT1 118/4885FLT4 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.